All In Biotech

FDA programs

What is a PDUFA date? How FDA action dates work

What is a PDUFA date? It is FDA's target date to act on a drug or biologic application. How review clocks are set, what moves them and where to find them.

By the All In Biotech editorial team · Published November 18, 2026 · 6 min read

A PDUFA date is the target date by which FDA aims to act on an application to market a new drug or biologic. The name comes from the Prescription Drug User Fee Act, under which companies pay fees and FDA commits to review timelines, usually 10 months for a standard review and 6 months for a priority review. On or before that date FDA either approves the application or sends a complete response letter.

This guide explains how the date is set, what can change it, and where to find upcoming dates.

Where PDUFA dates come from

Congress first passed the Prescription Drug User Fee Act in 1992. It lets FDA collect fees from companies that submit drug and biologic applications, and in return FDA agrees to performance goals, set out in a "commitment letter" negotiated with industry and sent to Congress.

The law has to be reauthorized every five years. The current version, PDUFA VII, covers fiscal years 2023 through 2027, so the next reauthorization is due in 2027 and the goals may change. FDA keeps the current goals letter and performance reports on its PDUFA page.

The goals are not legal deadlines. They are commitments to act on a set share of applications (90 percent for most review goals) within the target time. "PDUFA date" is the industry's name for the goal date for one application.

How the review clock is set

The clock depends on the type of application and whether FDA grants priority review.

ApplicationStandard reviewPriority reviewClock starts
New molecular entity NDA or original BLA (under "the Program")10 months6 months60-day filing date
Other original NDA (not a new molecular entity)10 months6 monthsDate FDA receives it
Efficacy supplement (new use, population or dose)10 months6 monthsDate FDA receives it
Class 1 resubmission after a complete response letter2 months2 monthsDate FDA receives it
Class 2 resubmission after a complete response letter6 months6 monthsDate FDA receives it

The first row is the one most news coverage refers to. For new molecular entities and original biologics, FDA has 60 days to decide whether to file the application for review. The 10-month or 6-month clock starts from that filing date, so in practice a standard review of a new drug runs about 12 months from submission and a priority review about 8 months.

FDA calls the review model for these applications "the Program": it adds pre-submission meetings, a mid-cycle communication and a late-cycle meeting with the company, and in exchange its review clock starts at the filing date rather than the date of receipt.

Priority review

FDA grants priority review when a drug, if approved, would be a significant improvement in the safety or effectiveness of treating a serious condition. FDA decides at filing, and companies usually announce the result, along with the goal date, when FDA accepts the application.

A priority review voucher lets a company get priority review for an application that would not otherwise qualify. Congress created vouchers for developers of certain tropical disease, rare pediatric disease and medical countermeasure products, and their eligibility rules have changed over time.

Priority review is common among new drugs. In this site's data, as of November 2026, 41 original approvals in 2025 and 32 so far in 2026 received priority review, and 31 of the 48 novel approvals of 2026 that we matched to Drugs@FDA records were priority reviews. For how priority review differs from breakthrough therapy, fast track and accelerated approval, see FDA expedited programs compared.

What can move a PDUFA date

  • Major amendment. If the company submits a major amendment within the last three months of the review, FDA can extend the goal date by three months. Companies usually announce these extensions.
  • Early action. FDA can act before the goal date, and sometimes does.
  • Missed goals. FDA occasionally acts after the goal date, for example because of a pending inspection or a late-stage question. The application stays under review.
  • Advisory committee. FDA may ask an advisory committee of outside experts for a vote. The meeting usually falls weeks or months before the goal date. FDA is not bound by the vote.
  • Newer pilot programs. In 2025 FDA announced a Commissioner's National Priority Voucher pilot that aims for much faster reviews for selected drugs. Programs like this are new and change often, so check fda.gov for current rules.

What happens on the date

FDA takes one of two actions:

  1. Approval. FDA sends an approval letter and the approved label. The approval is then added to Drugs@FDA. See how to search Drugs@FDA.
  2. Complete response letter (CRL). FDA explains what stands in the way of approval, such as the need for another trial, manufacturing problems found during inspection, or labeling issues. The company can resubmit, which starts a new 2-month or 6-month clock depending on what the response contains.

Historically, CRLs were confidential and the public learned of them from company statements. In 2025 FDA began publishing CRLs through openFDA, including some for applications that were never approved, and said it would release new letters promptly.

Silence is not a decision. If a date passes with no news, the most likely explanations are that FDA has not acted yet or that the company has not disclosed the outcome.

Where to find PDUFA dates

FDA does not publish a calendar of goal dates. Applications under review are confidential, and FDA generally does not confirm that one exists. The dates you see come from the companies:

  • Press releases when FDA accepts an application for filing, usually naming the goal date and whether review is priority or standard.
  • SEC filings such as 10-Q and 8-K reports from public companies, searchable on EDGAR.
  • Earnings calls and investor presentations.
  • FDA's advisory committee calendar, which shows meetings but not goal dates.

Large companies often give only a quarter or half-year ("a decision is expected in the first half of 2027"). Private companies may say nothing.

How to read a PDUFA date carefully

  • Check the source date. A goal date announced at filing may have been extended since. Look for the most recent company statement.
  • Check what is being reviewed. Many announced dates are for supplements adding a new use to an approved drug, not for new drugs.
  • Check the center. Vaccines and cell and gene therapies are reviewed by CBER, and their approvals are announced on CBER's pages, not in Drugs@FDA.
  • Do not infer the outcome from the timing. An early action, a delay or a quiet date says little on its own about whether the drug will be approved.

Recent volume of approvals

To give a sense of scale, CDER's Novel Drug Approvals list counted 50 new drugs in 2024 and 46 in 2025, and 53 in 2026 through November 17. Each was reviewed against a PDUFA goal date, but novel drugs are only part of the picture: across all original approvals and efficacy supplements, this site tracks 7,565 approvals since 2000.

For researchers following a company's upcoming decisions, the guide to researching a biotech pipeline with free data shows how to combine PDUFA dates with trial records and approval histories.

Frequently asked questions

What is a PDUFA date?
It is the goal date by which FDA aims to act on a drug or biologic application under the review timelines agreed in the Prescription Drug User Fee Act.
Does FDA always decide by the PDUFA date?
FDA meets most of its goals, but it can act early, act late, or extend the date by three months if a major amendment arrives near the end of the review.
Where can I find upcoming PDUFA dates?
FDA does not publish them. Companies announce them in press releases and filings, and calendars such as this site's PDUFA calendar compile those announcements.
What happens on a PDUFA date?
FDA either approves the application or issues a complete response letter explaining what must be fixed before approval.

For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.

Keep reading